Neumora Therapeutics, Inc. (NMRA)
↓ Download CSVKey ratios (FY2025)
-228.1%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Income | -$241.16M | -$263.46M | -$252.10M | -$135.87M | — |
| Net Income | -$236.93M | -$243.79M | -$235.93M | -$130.90M | — |
| EPS (Diluted) | $-1.45 | $-1.53 | $-3.63 | $-4.81 | — |
| Total Assets | $191.05M | $316.97M | $496.19M | $426.23M | — |
| Total Liabilities | $87.18M | $29.91M | $27.12M | $29.40M | — |
| Shareholders' Equity | $103.87M | $287.06M | $469.08M | -$446.85M | -$325.22M |
| Cash & Equivalents | $182.53M | $142.15M | $374.04M | $240.94M | — |
| Operating Cash Flow | -$206.44M | -$182.94M | -$163.28M | -$114.90M | — |
| Capital Expenditures | — | — | $117.0K | $511.0K | — |
| Shares Outstanding | 174.26M | 161.71M | 158.83M | 32.61M | — |